Create a toolbox of validated instruments for common CKD G4+ symptoms that can be used in trials or in supporting studies KDIGO* * Although KDIGO could act as a catalyst to establish these initiatives, they will likely require the creation of a dedicated organization or structure to ensure sustainability. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; ISN, International Society of Nephrology, ASN, American Society of Nephrology. In secondary prevention low-dose aspirin therapy reduces the incidence of adverse cardiovascular events and allcause mortality. S2 In primary prevention the evidence does not support the universal use or avoidance of aspirin. A systematic review (3 studies, n=4468) found no clear benefit of aspirin for the primary prevention of cardiovascular events in CKD and no statistically significant reduction in mortality. Major bleeding events were significantly increased with aspirin.
S3
Both KDIGO S4 and NICE S5 recommend that aspirin is indicated for secondary but not primary prevention. NICE have recommended future research to address this question for those at highest risk of cardiovascular disease (What is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?)
Bicarbonate therapy in CKD G4+
A meta-analysis of 6 studies (n=312) concluded that bicarbonate therapy was associated with improvement in kidney function and possibly a reduction in progression of CKD. S6 However, differences in study protocols and small sample sizes precluded definitive conclusions.
KDIGO suggest treatment with oral bicarbonate supplementation in people with CKD and serum bicarbonate concentrations < 22 mmol/l; NICE suggest considering oral sodium bicarbonate supplementation in people with CKD G4+ and a serum bicarbonate concentration of < 20 mmol/l.
Treatment of asymptomatic hyperuricemia
A systematic review (24 studies n=25,453) found that elevated serum uric acid levels were significantly associated with risk of mortality in patients with CKD.
S7
Another systematic review (13 studies, n=190,718) found a significant positive association with new-onset CKD at follow-up.
S8
However there is little evidence to justify uric acid-lowering in CKD G4+. Recent systematic review and RCT evidence on allopurinol use are inconsistent in terms of the potential benefits of lowering uric acid. S9-S13 KDIGO suggested there is insufficient evidence to support or refute the use of agents to lower serum uric acid concentrations in people with CKD and either symptomatic or asymptomatic hyperuricemia in order to delay progression of CKD. NICE make no recommendation but suggested that in people with CKD who are at high risk of progression, the clinical and cost effectiveness of uric acid-lowering agents on the progression of CKD and on mortality should be the subject of further research.
Metformin therapy in people with diabetes and CKD G4+
Metformin is widely prescribed given evidence suggesting it reduces the risk of myocardial infarction, stroke, atrial fibrillation and all-cause mortality.
S14
However its use in CKD has been limited because of the perceived increased risk of lactic acidosis. A Cochrane analysis of 347 controlled studies covering 70,490 patient-years of metformin use revealed no cases of lactic acidosis and no significant change in plasma lactate. S15 A Swedish Diabetes Registry study suggested that metformin was well tolerated in people with CKD G3, and its use was associated with 13% lower allcause mortality in this population. S16 Blood levels of metformin are influenced by kidney function and the main problem for metformin treatment in CKD G4+ is the prevention of intoxication. Recently published dosage guidelines suggest a maximum of 1 g daily in CKD G4+. Table S8 . Recommendations from the Renal Physicians Association regarding forgoing dialysis
S23
If appropriate, forgo dialysis for patients with CKD or ESRD in certain, well-defined situations:
• Patients with decision-making capacity, who being fully informed and making voluntary choices, refuse dialysis
• Patients who no longer possess decision-making capacity who have previously indicated refusal of dialysis in an oral or written advance directive
• Patients who no longer possess decision-making capacity and whose properly appointed legal surrogates refuse dialysis
• Patients with irreversible, profound neurological impairment such that they lack signs of thought, sensation, purposeful behavior, and awareness of self and environment.
Consider forgoing dialysis for CKD or ESRD patients who have a very poor prognosis or for whom dialysis cannot be provided safely. Included in these categories of patients are the following:
• Those whose medical condition precludes the technical process of dialysis because the patient is unable to cooperate (e.g., advanced dementia patient who pulls out dialysis needles or profound hypotension)
• Those who have a terminal illness from non-renal causes (acknowledging that some in this condition may perceive benefit from and choose to undergo dialysis)
• Those with CKD G5 older than age 75 years who met two or more of the following statistically significant very poor prognosis criteria: 1) clinician response of "No" to the 'surprise' question, 2) high comorbidity score, 3) significantly impaired functional status (e.g., Karnofsky score less than 40), 4) severe chronic malnutrition (e.g., serum albumin < 2.5 g/dl).
Forgo dialysis if initiating or continuing dialysis is deemed to be harmful, of no benefit, or merely prolongs a child's dying process. The decision to forgo dialysis must be made in consultation with the child's parents. Give children and adolescents the opportunity to participate in the decision to forgo dialysis to the extent that their developmental abilities and health status allow.
Consider forgoing dialysis in a patient with a terminal illness whose long term prognosis is poor if the patient and the family are in agreement with the physician that dialysis would not be of benefit or the burdens would outweigh the benefit.
Develop a palliative care plan for all pediatric patients with ESRD from the time of diagnosis and for children with AKI who forgo dialysis. The development of a palliative care plan is a continuation of the process of advance care planning and should be family-centered.
AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease. 
